Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Sander, Brooks"'
Autor:
Clemens, Muehlan, Sander, Brooks, Cedric, Vaillant, Michael, Meinel, Gabriël E, Jacobs, Rob G, Zuiker, Jasper, Dingemanse
Publikováno v:
Clinical Pharmacology and Therapeutics, 111(6), 1334-1342. Wiley-Blackwell
Use of hypnotics is often associated with next-morning residual effects and a higher risk of motor vehicle accidents. Measuring next-morning effects on driving performance is therefore advised by regulatory agencies. Here, we examined driving perform
Autor:
Rob Zuiker, Benjamin Berger, Sander Brooks, Muriel Richard, Clemens Muehlan, Jasper Dingemanse
Publikováno v:
CNS Drugs. 34:1253-1266
Daridorexant (ACT-541468) is a potent dual orexin receptor antagonist under development for the treatment of sleep disorders. Concomitant intake of ethanol and hypnotics has been shown to result in additive/supra-additive depression of the central ne
Autor:
Henriëtte S de Bruijn, Sander Brooks, Angélique van der Ploeg-van den Heuvel, Timo L M Ten Hagen, Ellen R M de Haas, Dominic J Robinson
Publikováno v:
PLoS ONE, Vol 11, Iss 2, p e0148850 (2016)
BACKGROUND:Light fractionation significantly increases the efficacy of 5-aminolevulinic acid (ALA) based photodynamic therapy (PDT) using the nano-emulsion based gel formulation BF-200. PDT using BF-200 ALA has recently been clinically approved and i
Externí odkaz:
https://doaj.org/article/ca373e4cf5d64fe99e0de301e9ac5466
Autor:
Michelle Mellion, Sander Brooks, Diego Cadavid, Shane Raines, Michelle Hage, Geert Jan Groeneveld, Cécile Berends, William G Tracewell, Adefowope Odueyungbo, Lorin A. Thompson, Lucienne Ronco, Michiel J van Esdonk, Lisa Pagan, Umesh A. Badrising, Emilie M J van Brummelen, Baziel G.M. van Engelen
Publikováno v:
British Journal of Clinical Pharmacology, 87(12), 4658-4669. WILEY
Aims Evaluate safety, tolerability, pharmacokinetics (PK) and target engagement (TE) of losmapimod in blood and muscle in facioscapulohumeral dystrophy (FSHD). Methods This study included Part A: 10 healthy volunteers randomized to single oral doses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc884dc6eac870563f6d4cc46fe9b44f
http://hdl.handle.net/1887/3248780
http://hdl.handle.net/1887/3248780
Autor:
Wayne C. Drevets, Koen Schruers, Anantha Shekhar, Sander Brooks, Philip L. Johnson, John A. Moyer, Brock T. Shireman, Cathy Bleys, Luc Van Nueten, Bart Remmerie, Diane Nepomuceno, Lebold Terry Patrick, Rob Zuiker, Giacomo Salvadore, Brian Lord, Abigail I. Nash, Christine Dugovic, Kanaka Tatikola, Gabriel E. Jacobs, Pascal Bonaventure
Publikováno v:
Translational Psychiatry
Translational Psychiatry, Vol 10, Iss 1, Pp 1-10 (2020)
Translational Psychiatry, 10(1). NATURE PUBLISHING GROUP
Translational Psychiatry, 10(1):308. Nature Publishing Group
Translational Psychiatry, Vol 10, Iss 1, Pp 1-10 (2020)
Translational Psychiatry, 10(1). NATURE PUBLISHING GROUP
Translational Psychiatry, 10(1):308. Nature Publishing Group
Orexin neurons originating in the perifornical and lateral hypothalamic area project to anxiety- and panic-associated neural circuitry, and are highly reactive to anxiogenic stimuli. Preclinical evidence suggests that the orexin system, and particula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b397cd405d1b36d3e9fc6b0fedee7f63
https://hdl.handle.net/1887/3184546
https://hdl.handle.net/1887/3184546
Autor:
P. Van der Ark, Gabriel E. Jacobs, I. Kezic, J.M.A. van Gerven, Sander Brooks, A Savitz, Rob Zuiker
Publikováno v:
Sleep. 44:A136-A136
Introduction Seltorexant (JNJ-42847922), a potent and selective antagonist of the human orexin-2 receptor, is being developed for the treatment of major depressive disorder. Seltorexant also has sleep-promoting properties. Investigating the effects o
Autor:
Joop M. A. van Gerven, Sander Brooks, Margaux Boehler, Jasper Dingemanse, Rob Zuiker, Clemens Muehlan
Publikováno v:
Journal of Psychopharmacology, 34(3), 326-335. SAGE PUBLICATIONS LTD
Background: The dual orexin receptor antagonist ACT-541468 showed sedative pharmacodynamic effects during initial clinical testing in adult subjects. The present study explored pharmacokinetics, pharmacodynamics and tolerability in healthy elderly su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8268d69417432eaaad1bb072888efbdb
https://hdl.handle.net/1887/3181508
https://hdl.handle.net/1887/3181508
Autor:
I. Kezic, Sander Brooks, Rob Zuiker, Joop M. A. van Gerven, Peter de Boer, Wayne C. Drevets, Remy Luthringer, Peter van der Ark, Justine M. Kent, Luc Van Nueten, Guido van Amerongen, Gabriel E. Jacobs
Publikováno v:
Journal of Psychopharmacology, 33(2), 202-209
Background: Insomnia is common in patients with major depressive disorder. Although antidepressants improve mood, insomnia often persists as a result of physiological hyperarousal. The orexin-2 receptor is increasingly being recognized as a new targe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8373ae9a16200258305ec1e18d2b3cf
https://hdl.handle.net/1887/119782
https://hdl.handle.net/1887/119782
Publikováno v:
European Neuropsychopharmacology, 29(7), 847-857. ELSEVIER SCIENCE BV
ACT-541468 is a dual orexin receptor antagonist with sleep-promoting effects in humans. Following entry-into-humans, its pharmacokinetics (PK) including dose-proportionality and accumulation, pharmacodynamics (PD), safety, and tolerability following
Autor:
Gabriel E. Jacobs, Kanaka Tatikola, Bart Remmerie, Bleys Cathy, Wayne C. Drevets, Giacomo Salvadore, Luc Van Nueten, John A. Moyer, Sander Brooks, Shireman Brock T, Pascal Bonaventure
Publikováno v:
Biological Psychiatry. 85:S217-S218